PureTech to Present LYT-200 Phase 1b Results in MDS, AML at ESMO 2026

Bitget2026/10/19 06:10

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

PureTech Health will present Phase 1b LYT-200 results at ESMO in Madrid on October 24, 2026.
Results showed encouraging clinical activity with favorable safety in heavily pretreated patients with relapsed/refractory high-risk myelodysplastic syndromes and acute myeloid leukemia.
Gallop Oncology plans to advance LYT-200 into the Phase 2 STRIDE-MDS trial for relapsed/refractory high-risk myelodysplastic syndromes following FDA discussions.
The drug received FDA Fast Track designation, supporting development in a population with limited treatment options.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PureTech Health plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202610190200BIZWIRE_USPR_____20261018_BW068368) on October 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

PureTech to Present LYT-200 Phase 1b Results in MDS, AML at ESMO 2026

You may also like

Crypto prices